Skip to content

EVACUATE-pilot - Ultra-Early, minimally inVAsive intraCerebral haemorrhage evacUATion versus standard trEatment (EVACUATE)-Pilot phase

Ultra-Early, minimally inVAsive intraCerebral haemorrhage evacUATion versus standard trEatment (EVACUATE)-Pilot phase A phase IIa pilot feasibility study of ultra-early minimally invasive haematoma evacuation within 12 hours of intracerebral haemorrhage

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12619001748101
Acronym
EVACUATE-Pilot
Enrollment
14
Registered
2019-12-10
Start date
2019-12-16
Completion date
2020-09-30
Last updated
2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This trial is a phase IIa study of ultra-early minimally invasive haematoma removal acutely following ICH. The aim of the study is to demonstrate feasibility, safety and preliminary efficacy of this treatment in patients with acute intracerebral supratentorial haemorrhage of greater than 20mL volume and less than 12 hours duration.

Interventions

Positioning and planning Using standard of care volumetric imaging, a line is extended through the long axis of the clot to the nearest skull surface to maximize hematoma access in a single dimension while minimizing the traversed brain, and avoiding prominent vasculature and the corticospinal tract. Approaches must avoid eloquent brain regions including the primary motor and sensory cortices, language regions, and visual cortex. Stereotactic guidance must be used during the procedure for preope

Positioning and planning Using standard of care volumetric imaging, a line is extended through the long axis of the clot to the nearest skull surface to maximize hematoma access in a single dimension while minimizing the traversed brain, and avoiding prominent vasculature and the corticospinal tract. Approaches must avoid eloquent brain regions including the primary motor and sensory cortices, language regions, and visual cortex. Stereotactic guidance must be used during the procedure for preoperative trajectory planning and intraoperative live navigation. Surgical Approach A linear incision is made in the skin and a high-speed or perforator drill is used to create a 1-2 cm diameter craniectomy. When the trajectory is not perfectly perpendicular to the skull, extra care must be taken to drill away a cylinder in the bone along the planned trajectory to maximize mobility of the sheath and endoscope within the craniectomy. Hemostasis is attained with bone wax, gel foam, and bipolar cautery. Prior to dural incision, ultrasound may be used to confirm the haematoma size and location for comparison after evacuation. The dura is incised and cauterized. The pia is incised. A brain biopsy may be performed for diagnostic purposes. The pia is then cauterized and hemostasis is achieved prior to passing the Surgiscope into the hematoma. The trajectory is planned such that the tip of the surgiscope obdurator will rest 1-2 cm from the distal end of the hematoma. The surgiscope is passed along the preplanned trajectory under live stereotactic guidance. The clear obdurator will show the red color of the clot as the surgiscope passes through it. The obdurator is then removed. The Aurora evacuator is introduced and clot is aspirated. Irrigation can be activated through the evacuator to improve visibility of the clot-brain border and to localize bleeding vessels. If a bleeding vessel is identified, bipolar cautery is used to cauterize the vessel under direct visualization. Given the inflammatory consequence of using thrombin in the cavity, the use of thrombin in the cavity is strongly discouraged. After hematoma is aspirated, reduced mass effect causes the surrounding brain to collapse inward and come into view at the end of the sheath. Once this occurs, the sheath is gently pivoted at the same depth to explore laterally to the sides of the hematoma cavity. Once the operator is convinced there is no remaining hematoma at that depth, the sheath is drawn back 1-2cm and the process is repeated. If, during this phase, a solid clot is encountered, the Aurora agitator is activated to digest more fibrous clot pieces. A large gauge suction and bipolar cautery may also be used if the Aurora evacuator is unable to aspirate a large clot fragment. After clearing all visible clots by withdrawing incrementally from the distal end of the hematoma, the cavity may be irrigated heavily with lactated Ringer’s solution to evaluate for residual clot fragments and active bleeding vessels. Assessment and closure After aspiration of all visible clots, the device is removed and the burr hole ultrasound may be used to assess for residual haematoma. The ultrasound may be helpful to reassess the degree of evacuation and settle any doubt about questionable regions seen through the surgiscope. An intraoperative CT is then performed to confirm that the goal of residual hematoma less than or equal to 15 ml or <50% of initial haematoma volume has been achieved. If the CT demonstrates that the residual clot volume is greater than 15 ml or >50% of initial haematoma volume then a second pass for additional clot removal is recommended (followed by an additional CT scan post procedure). A third pass is not recommended. Intraoperative CT scans can either be performed in operating room or angiography suite prior to closure or it can be performed in a traditional CT scanner with the operating room remaining sterile to permit return to the OR if the evacuation is not satisfactory. After completing the evacuation, hemostasis of the brain surface at the craniectomy site is confirmed. Dural substitute can be used at the preference of the surgeon. A titanium plate is used to cover the craniectomy defect and secured in place with titanium screws. The galea and skin are closed with sutures or staples per surgeon preference.

Sponsors

royal adelaide hospital
Lead SponsorHospital

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients presenting with an acute spontaneous supratentorial ICH >=20mL in volume 2. Age greater than or equal to 18 years 3. Surgery can commence within 12 hours of symptom onset (or in patients with unknown time of symptom onset, the time patient was last known to be well) OR in patients presenting with small ICH (volume <20mL) with clinical deterioration judged due to ICH haematoma expansion meeting volume criteria, within 12 hours of clinical deterioration 4. Moderate to severe neurological deficit (NIHSSgreater than or equal to 6) 5. CTA or MRA is performed and does not show an underlying vascular lesion

Exclusion criteria

1. Glasgow coma scale (GCS) of 3 unless procedure can be commenced within 1 hour of deterioration to this level 2. Brainstem ICH (minimal brainstem extension of a thalamic ICH is allowed) 3. ICH secondary to trauma, where brain injury is judged more likely to be due to the broad effects of trauma rather than the focal ICH, 4. Hereditary or acquired haemorrhagic diathesis or coagulation factor deficiency (in liver diease, INR>1.5). 5. Platelet count <75,000 6. Unreversed heparinization or anticoagulation. An INR or less than 1.6 is required in the setting of reversed warfarinisation. Reversal of heparin by protamine, dabigatran by idarucizumab and rivaroxaban, apixaban and enoxaparin by andexanet (where available) is permitted. Unreversed anticoagulation with a last dose within 48 hours is an exclusion. 7. Recent (<12 hours) parenteral GPIIb/IIIa antagonist. 8. Recent (<1 hour) thrombolysis. If the ICH has occurred between 1 and 12 hours following thrombolysis cryoprecipitate (1U per 10kg) must be administered prior to treatment. 9. Participation in any investigational study in the last 30 days 10. Known terminal illness such that the patients would not be expected to survive a year. 11. Planned withdrawal of care or comfort care measures. 12. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 7, 2026